Transforming life for patients with Parkinson’s disease

Developing novel treatments for Parkinson’s disease, driving change for patients with the most troublesome symptoms: involuntary movements occurring upon long-term use of levodopa (LIDs) and impaired balance leading to falls.

Two clinical phase II candidates

Mesdopetam (IRL790) in development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease. Read more >

Pirepemat (IRL752) in development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease. Read more >

Proprietary technology platform

The research and development program is generated by the proprietary technology platform, the Integrative Screening Process (ISP). Read more >

We’re looking for an Analytical Chemist to join our team!

Read more >

Latest press release

IRLAB’s annual report for 2020 is now available on the company’s website

April 15, 2021

IRLAB (Nasdaq Stockholm: IRLAB A) announced today that the annual report for 2020 is published on www.irlab.se. In addition, the company’s website has been visually updated.

Read More >
Latest presentation

Interview with CEO and CFO regarding the December -20 share issue (Swedish)

December 21, 2020 Read More >